Supporting the South African HIV/TB Investment Case

Since 2011, UNAIDS and other international organisations have prompted countries to counter the downward trend in international funding for HIV programmes by developing an investment case for their national HIV responses. These cases aim to maximise the impact of programmes on HIV incidence and deaths by correcting any mismatch between the epidemic and the response, identifying how to go to the required scale and maintain it, cutting unnecessary costs and diversions of capacity while generating efficiencies, and ensuring the sustainability of programme funding. HE2RO is supporting the development of the Investment Case for South Africa, which aim is more specific: to establish the most cost-effective mix of interventions against HIV and TB for South Africa over the next 20 years, taking into account both current and future levels of technical efficiency. Cost effectiveness will be measured as cost per HIV or TB infection averted, as well as number of life years saved, by the entire programme of interventions. Results will inform national HIV and TB policy as well as domestic government budgets and funding proposals to international donors. HE2RO supports the investment case task team by coordinating all modelling efforts, using established models of the HIV and TB epidemics in South Africa, by developing a cost model that is purpose-built for this analysis, and through the collection and preparation of cost data.


The following publications emanate from this project:

Funded by


HE2RO staff involved

Professor Gesine Meyer-Rath  

Stay up to date

Receive newsletters and keep up to date with developments at HE2RO.